Home
About Us
About Antengene
Management Team
Board Of Directors
Scientific Advisory Board
Antengene Events
Investors
Company honor
Contact Us
Our Business
Discovery
Development
Manufacturing
Commercialization
Pipeline
Our Products
Newsroom
Partnerships
Partnering with Antengene
Partnership
Investor Relations
Announcements & Circulars
Corporate Governance
Financial Report
Webcast & Presentation
Event Calendar
Investor Contact
Career
Social Responsibility
Working at Antengene
Join Us
简
EN
Antengene Announces First Patient Dosed in the Phase I STAMINA-001 Study of ATG-037 for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors
May 31, 2022
View PDF
Back to list
About Us
About Us
Management Team
Board Of Directors
Scientific Advisory Board
antengene events
Investors
Company honor
Contact Us
Our Business
Discovery
Development
Manufacturing
Commercialization
Pipeline
Newsroom
Partnerships
Partnering with Antengene
Partnership
Investor Relations
Announcements & Circulars
Corporate Governance
Financial Report
Corporate Presentation
Event Calendar
Investor Contact
Career
Social Responsibility
Working at Antengene
Join Us
